Choice of testing ‘is becoming interesting’
With increasing genetic insights into hereditary breast cancer, clinicians must decide which of a variety of diagnostic and prognostic genetic test they should offer patients and their families.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
In this video, Holly Pederson, MD, Director of Cleveland Clinic’s Medical Breast Program and Hereditary High-Risk Program, discusses red flags that indicate heightened risk of hereditary breast cancer, and the range of genetic tests that are available.
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust